141 related articles for article (PubMed ID: 11962766)
1. Survivin--a universal tumor antigen.
Andersen MH; thor SP
Histol Histopathol; 2002 Apr; 17(2):669-75. PubMed ID: 11962766
[TBL] [Abstract][Full Text] [Related]
2. HLA-B35-restricted immune responses against survivin in cancer patients.
Reker S; Becker JC; Svane IM; Ralfkiaer E; Straten PT; Andersen MH
Int J Cancer; 2004 Mar; 108(6):937-41. PubMed ID: 14712500
[TBL] [Abstract][Full Text] [Related]
3. Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients.
Andersen MH; Pedersen LO; Capeller B; Bröcker EB; Becker JC; thor Straten P
Cancer Res; 2001 Aug; 61(16):5964-8. PubMed ID: 11507035
[TBL] [Abstract][Full Text] [Related]
4. Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer.
Jäger D; Jäger E; Knuth A
J Clin Pathol; 2001 Sep; 54(9):669-74. PubMed ID: 11533070
[TBL] [Abstract][Full Text] [Related]
5. An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin.
Hirohashi Y; Torigoe T; Maeda A; Nabeta Y; Kamiguchi K; Sato T; Yoda J; Ikeda H; Hirata K; Yamanaka N; Sato N
Clin Cancer Res; 2002 Jun; 8(6):1731-9. PubMed ID: 12060610
[TBL] [Abstract][Full Text] [Related]
6. Survivin-derived peptide epitopes and their role for induction of antitumor immunity in hematological malignancies.
Friedrichs B; Siegel S; Andersen MH; Schmitz N; Zeis M
Leuk Lymphoma; 2006 Jun; 47(6):978-85. PubMed ID: 16840186
[TBL] [Abstract][Full Text] [Related]
7. CTL-defined cancer vaccines: perspectives for active immunotherapeutic interventions in minimal residual disease.
Jäger E; Jäger D; Knuth A
Cancer Metastasis Rev; 1999; 18(1):143-50. PubMed ID: 10505552
[TBL] [Abstract][Full Text] [Related]
8. Phase I clinical trial of survivin-derived peptide vaccine therapy for patients with advanced or recurrent oral cancer.
Miyazaki A; Kobayashi J; Torigoe T; Hirohashi Y; Yamamoto T; Yamaguchi A; Asanuma H; Takahashi A; Michifuri Y; Nakamori K; Nagai I; Sato N; Hiratsuka H
Cancer Sci; 2011 Feb; 102(2):324-9. PubMed ID: 21143701
[TBL] [Abstract][Full Text] [Related]
9. Strategies for the development of vaccines to treat breast cancer.
Jäger E; Jäger D; Knuth A
Recent Results Cancer Res; 1998; 152():94-102. PubMed ID: 9928550
[TBL] [Abstract][Full Text] [Related]
10. Variable epitope library carrying heavily mutated survivin-derived CTL epitope variants as a new class of efficient vaccine immunogen tested in a mouse model of breast cancer.
NoeDominguez-Romero A; Zamora-Alvarado R; Servín-Blanco R; Pérez-Hernández EG; Castrillon-Rivera LE; Munguia ME; Acero G; Govezensky T; Gevorkian G; Manoutcharian K
Hum Vaccin Immunother; 2014; 10(11):3201-13. PubMed ID: 25483665
[TBL] [Abstract][Full Text] [Related]
11. Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin.
Wobser M; Keikavoussi P; Kunzmann V; Weininger M; Andersen MH; Becker JC
Cancer Immunol Immunother; 2006 Oct; 55(10):1294-8. PubMed ID: 16315030
[TBL] [Abstract][Full Text] [Related]
12. The universal character of the tumor-associated antigen survivin.
Andersen MH; Svane IM; Becker JC; Straten PT
Clin Cancer Res; 2007 Oct; 13(20):5991-4. PubMed ID: 17947459
[TBL] [Abstract][Full Text] [Related]
13. Identification of novel helper epitope peptides of Survivin cancer-associated antigen applicable to developing helper/killer-hybrid epitope long peptide cancer vaccine.
Ohtake J; Ohkuri T; Togashi Y; Kitamura H; Okuno K; Nishimura T
Immunol Lett; 2014 Sep; 161(1):20-30. PubMed ID: 24794408
[TBL] [Abstract][Full Text] [Related]
14. Naked DNA immunization as an approach to target the generic tumor antigen survivin induces humoral and cellular immune responses in mice.
Lladser A; Párraga M; Quevedo L; Carmen Molina M; Silva S; Ferreira A; Billetta R; G Quest AF
Immunobiology; 2006; 211(1-2):11-27. PubMed ID: 16446167
[TBL] [Abstract][Full Text] [Related]
15. Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors.
Lennerz V; Gross S; Gallerani E; Sessa C; Mach N; Boehm S; Hess D; von Boehmer L; Knuth A; Ochsenbein AF; Gnad-Vogt U; Zieschang J; Forssmann U; Woelfel T; Kaempgen E
Cancer Immunol Immunother; 2014 Apr; 63(4):381-94. PubMed ID: 24487961
[TBL] [Abstract][Full Text] [Related]
16. Cancer immunotherapy in clinical oncology.
Knuth A; Jäger D; Jäger E
Cancer Chemother Pharmacol; 2000; 46 Suppl():S46-51. PubMed ID: 10950148
[TBL] [Abstract][Full Text] [Related]
17. A potent immunogenic general cancer vaccine that targets survivin, an inhibitor of apoptosis proteins.
Idenoue S; Hirohashi Y; Torigoe T; Sato Y; Tamura Y; Hariu H; Yamamoto M; Kurotaki T; Tsuruma T; Asanuma H; Kanaseki T; Ikeda H; Kashiwagi K; Okazaki M; Sasaki K; Sato T; Ohmura T; Hata F; Yamaguchi K; Hirata K; Sato N
Clin Cancer Res; 2005 Feb; 11(4):1474-82. PubMed ID: 15746049
[TBL] [Abstract][Full Text] [Related]
18. Identification of a promiscuous HLA DR-restricted T-cell epitope derived from the inhibitor of apoptosis protein survivin.
Piesche M; Hildebrandt Y; Zettl F; Chapuy B; Schmitz M; Wulf G; Trümper L; Schroers R
Hum Immunol; 2007 Jul; 68(7):572-6. PubMed ID: 17584578
[TBL] [Abstract][Full Text] [Related]
19. The anti-tumor immune response induced by a combination of MAGE-3/MAGE-n-derived peptides.
Zhang XM; Zhang YF; Huang Y; Qu P; Ma B; Si SY; Li ZS; Li WX; Li X; Ge W; Hu PZ; Sui YF
Oncol Rep; 2008 Jul; 20(1):245-52. PubMed ID: 18575744
[TBL] [Abstract][Full Text] [Related]
20. Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo.
Jäger E; Ringhoffer M; Karbach J; Arand M; Oesch F; Knuth A
Int J Cancer; 1996 May; 66(4):470-6. PubMed ID: 8635862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
